Trial Profile
A phase I, randomised, cohort, single-dose, dose-escalation,cross-over study to evaluate the pharmacokinetics, glucodynamics, safety, and tolerability of Insulin peglispro [LY2605541] in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Insulin peglispro (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
- 09 Dec 2015 New trial record